Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers

Breast Cancer Research and Treatment, 05/03/2012

Emerging data suggests that crosstalk between these pathways is also involved in resistance to HER2–directed agents. Unraveling the role of the ER pathway in resistance to HER2–directed agents could potentially result in therapeutic approaches that can improve outcome for patients with ER–positive, HER2–positive breast cancer.

Print Article Summary Cat 2 CME Report